Methylxanthines and Breast Cancer
| Autor: | Jason Pozner, Papatestas Ae |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Gynecology
Oncology medicine.medical_specialty business.industry Cancer General Medicine medicine.disease Fibrocystic disease chemistry.chemical_compound Increased risk Breast cancer chemistry Caffeine consumption Internal medicine medicine Breast disease skin and connective tissue diseases Caffeine business Carcinogen |
| Zdroj: | JAMA: The Journal of the American Medical Association. 255:748 |
| ISSN: | 0098-7484 |
| Popis: | To the Editor.— In his reply to the question concerning estrogen therapy and breast cancer,1Dr Block states, "We have ample clinical and laboratory evidence to show that benign breast lesions are stimulated by xanthines," yet most reports show no significant correlation between fibrocystic disease and methylxanthine intake.2-5Dr Block further suggests that for prevention of breast cancer "a prudent physician would be well advised to counsel his patients to avoid xanthines." The relevance of methylxanthines to benign breast disease should not be extrapolated to breast cancer in the absence of hard evidence linking non-proliferative benign breast disease with increased risk of cancer.6The Fourth International Caffeine Workshop concluded that epidemiologic studies in humans have not established a causal relationship between caffeine consumption and breast cancer and that there was no evidence that caffeine has a carcinogenic potential, or that it functions as a mutagen in doses |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|